Order number: P2270.9501Shipping: shipped at RT, store at -20°C
Delivery time: 3- 8 working days
For detailed information on the delivery date, please contact Genaxxon.
|To 2||€145.00 *|
|From 3||€116.00 *|
Prices plus VAT plus shipping costs
MOG (183-191) FVIVPVLGP represents a short peptide sequence of the protein lipid part of the myelin sheath. Such proteins are obviously targets of the immune defense in multiple sclerosis.
Multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS), is characterised by primary demyelination. It is widely thought that this is the result of an autoimmune attack against myelin components. Potential target antigens in MS are proteins of the myelin sheath such as myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), and proteolipid protein (PLP). Experimental autoimmune encephalomyelitis (EAE) has proven to be a particularly useful animal model. T cell epitopes of MOG for the induction of EAE in mice have been identified. Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) ChemMedChem 2, 1674-1692.
Purity: >95% (HPLC, 214nm)
Appearance: lyophilized white powder
Sicherheits Hinweise / Safety
Klassifizierungen / Classificationeclass-Nr: 34-16-04-90
Dokumente - Protokolle - Downloads
Here you will find information and further literature on MOG (183-191) FVIVPVLGP. For further documents (certificates with additional lot numbers, safety data sheets in other languages, further product information) please contact Genaxxon biosience at: email@example.com or phone: +49 731 3608 123.